Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521800 | 0.98 | LMNA (0.44) | LMNATSHRMTNR1APRCPNOS2 | |
| SCHEMBL21400551 | 0.95 | LMNA (0.47) | LMNATSHRMTNR1APRCPNOS2 | |
| SCHEMBL666973 | 0.87 | MTNR1A (0.40) | LMNATSHRMTNR1ANOS2SMYD3 | |
| SCHEMBL19774297 | 0.86 | MTNR1A (0.47) | LMNATSHRMTNR1ASMYD3MAPT | |
| SCHEMBL5208272 | 0.81 | TSHR (0.49) | LMNATSHRPRCPNOS2MAPT | |
| SCHEMBL5208279 | 0.81 | TSHR (0.49) | LMNATSHRPRCPNOS2MAPT | |
| SCHEMBL5213527 | 0.81 | TSHR (0.49) | LMNATSHRPRCPNOS2MAPT | |
| SCHEMBL26075115 | 0.80 | TSHR (0.47) | LMNATSHRPRCPNOS2MAPT | |
| SCHEMBL667641 | 0.79 | MTNR1A (0.40) | LMNATSHRMTNR1ASMYD3MAPT | |
| SCHEMBL5880335 | 0.78 | TSHR (0.45) | LMNATSHRPRCPNOS2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772227-B2 | Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists | N.V. ORGANON (NL) | 2010-08-10 | — | — | US | disclosed |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | AKZO NOBEL N.V. (NL) | 2007-04-19 | — | — | US | disclosed |
| EP-1696930-B1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | ORGANON NV (NL) | 2007-04-11 | — | — | EP | disclosed |
| EP-1696930-A1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | Akzo Nobel N.V. (NL) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058327-A1 | TRICYCLIC 1-[(3-INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | AKZO NOBEL N.V. (NL) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | OPRD1, OPRK1, OPRM1 | LMNA 2956/4885TSHR 883/4885MTNR1A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.